NPCE
NeuroPace Inc

316
Mkt Cap
$335.12M
Volume
50,974.00
52W High
$18.98
52W Low
$6.03
PE Ratio
-12.16
NPCE Fundamentals
Price
$9.88
Prev Close
$10.13
Open
$10.05
50D MA
$10.06
Beta
1.15
Avg. Volume
183,068.62
EPS (Annual)
-$0.9318
P/B
17.22
Rev/Employee
$434,271.74
Loading...
Loading...
News
all
press releases
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of...
Business Wire·8d ago
News Placeholder
More News
News Placeholder
NeuroPace to Participate in Upcoming Healthcare Conferences
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in two healthcare...
Business Wire·2mo ago
News Placeholder
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of -8.33% and +0.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +28.57% and +10.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of +14.63% and -0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates
Orthofix (OFIX) delivered earnings and revenue surprises of +225.00% and +3.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +76.92% and +7.52%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
Zacks·5mo ago
News Placeholder
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Zacks·6mo ago
News Placeholder
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago

Latest NPCE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.